Hemispherx Biopharma Inc (HEB): Thomas K. Equels , CEO of Hemispherx Biopharma Inc purchased 48,000 shares on Jul 8, 2016. The Insider buying transaction was reported by the company on Jul 8, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.12 per share for a total value of $5,683.20 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 1, 2016, Thomas K. Equels (CEO) purchased 171,000 shares at $0.12 per share price.On Aug 20, 2015, William A Carter (CEO) purchased 25,000 shares at $0.18 per share price.
Shares of Hemispherx BioPharma Inc (HEB) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.0004 points or -0.33% at $0.1195 with 6,31,653 shares getting traded. Post opening the session at $0.122, the shares hit an intraday low of $0.1105 and an intraday high of $0.1241 and the price vacillated in this range throughout the day. The company has a market cap of $30 M and the number of outstanding shares has been calculated to be 24,79,18,530 shares. The 52-week high of Hemispherx BioPharma Inc is $0.2136 and the 52-week low is $0.0604.
Hemispherx Biopharma Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s flagship products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS (Chronic Fatigue Syndrome). The Company’s Alferon LDO (Low Dose Oral) is an experimental liquid natural interferon for oral administration.